Kisunla | ALZFORUM
Aug 17, 2020 · Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologic drug recognizes Aβ (p3-42), a pyroglutamate form of Aβ that is …
Donanemab Approved in the U.S. - ALZFORUM
Donanemab has become the second anti-amyloid immunotherapy to win traditional approval from the U.S. Food and Drug Administration. The antibody, which will be marketed as Kisunla, got the official …
And Then There Were Three: Donanemab Phase 3 Trial Positive
May 4, 2023 · The donanemab Phase 3 trial is a major accomplishment on many levels: its unequivocal success in demonstrating clinical benefit, the fact that Lilly was able to conduct and complete a very …
Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab
Unlike donanemab, remternetug has been designed to be injected under the skin (Apr 2023 conference news). In Madrid, Kevin Biglan at Lilly described a new, global Phase 3 trial, Trailrunner-Alz3. …
FDA Approves Safer, Slower Donanemab Titration | ALZFORUM
Jul 24, 2025 · Liu said for this reason, many of the donanemab patients at his clinic are APOE4 homozygotes. Robert Przybelski at the University of Wisconsin, Madison, believes that lecanemab, …
Lecanemab Bested Three Other Antibodies at Binding Soluble Aβ ...
Oct 22, 2024 · Previously, Lars Lannfelt at Uppsala University, Sweden, who started the development of lecanemab, had reported that the antibody bound Aβ protofibrils more strongly than did aducanumab …
Donanemab: Small Tweak in Titration, Big Gain in Safety?
When donanemab was titrated up in steps, ARIA-E risk dropped. For APOE4 homozygotes, risk fell to nearly the level in heterozygotes. New donanemab AUR are stricter than the label, emphasizing safety.
Donanemab Approval Likely to Pose New Quandaries for Clinicians
Jun 25, 2024 · Donanemab has also been shown to clear plaque by stimulating microglia to gobble it up. How to Minimize Risk? As with other antRi-amyloid antibodies, safety was a major concern. …
Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit
Apr 6, 2021 · In a Phase 2 trial, donanemab completely cleared plaque in two-thirds of participants. Their cognitive decline slowed by a third, meeting the primary endpoint. The treatment appeared to …
In Phase 2, Donanemab Curbs Cognitive Decline in Early ... - ALZFORUM
Jan 12, 2021 · The Alzheimer’s field begins 2021 with a glimmer of good news: Donanemab, a monoclonal antibody that recognizes a pyroglutamated form of Aβ, slowed cognitive decline in …